Drug Trial Radar · NCT05636306
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Nov 22, 2022
Primary completion
Oct 5, 2023
Study completion Oct 5, 2023
Sponsor
- Lead sponsor
- NoNO Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults. Participants will be administered a single intravenous dose of NoNO-42 or placebo. Participants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day 28.
Conditions
- First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
Interventions
NoNO-42Drug
A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
PlaceboDrug
A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of AEs, abnormal laboratory findings and abnormal vital signsTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences Company Inc.
Mount Royal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.